Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed EBT Margin for 4 consecutive years, with 3164.3% as the latest value for Q3 2023.

  • On a quarterly basis, EBT Margin changed N/A to 3164.3% in Q3 2023 year-over-year; TTM through Mar 2025 was 106.39%, a 439150.0% increase, with the full-year FY2024 number at 12.16%, up 345790.0% from a year prior.
  • EBT Margin was 3164.3% for Q3 2023 at Fulcrum Therapeutics, up from 9471.19% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 354.96% in Q1 2021 to a low of 9471.19% in Q1 2023.
  • A 4-year average of 1818.63% and a median of 892.28% in 2020 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: soared 210531bps in 2021, then plummeted -847088bps in 2023.
  • Fulcrum Therapeutics' EBT Margin stood at 419.41% in 2020, then fell by -11bps to 464.29% in 2021, then tumbled by -290bps to 1810.31% in 2022, then plummeted by -75bps to 3164.3% in 2023.
  • Per Business Quant, the three most recent readings for FULC's EBT Margin are 3164.3% (Q3 2023), 9471.19% (Q1 2023), and 1810.31% (Q2 2022).